HK50996A - Treatment of gastrointestinal disorders using 5-ht3 antagonists - Google Patents

Treatment of gastrointestinal disorders using 5-ht3 antagonists Download PDF

Info

Publication number
HK50996A
HK50996A HK50996A HK50996A HK50996A HK 50996 A HK50996 A HK 50996A HK 50996 A HK50996 A HK 50996A HK 50996 A HK50996 A HK 50996A HK 50996 A HK50996 A HK 50996A
Authority
HK
Hong Kong
Prior art keywords
use according
diarrhea
methyl
carboxylic acid
indol
Prior art date
Application number
HK50996A
Other languages
German (de)
English (en)
Inventor
Buchheit Karl-Heinz
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19843446484 external-priority patent/DE3446484A1/de
Priority claimed from DE19853531282 external-priority patent/DE3531282A1/de
Priority claimed from DE19853531281 external-priority patent/DE3531281A1/de
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HK50996A publication Critical patent/HK50996A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Claims (18)

1. L'utilisation d'un composé de formule dans laquelle le groupe -CO-Y-D est situé à l'une des positions 3, 4 ou 5 du système bicyclique,
Z signifie -NR3-, ou -S-,
R1 et R2 , indépendamment, signifient l'hydrogène, un halogène ou un groupe alkyle en C1-C4 ou alcoxy en Ci -C4 , R1 étant en position 4 ou 5,
R3 signifie l'hydrogène ou un groupe alkyle en C1-C4,
Y signifie -O- ou -NH-, et
D signifie un groupe de formule VI
dans laquelle n signifie 2, 3 ou 4, et
R8 signifie l'hydrogène ou un groupe alkyle en C1-C4 ou benzyle, ou un sel d'addition d'acide ou un sel d'ammonium quaternaire pharmaceutiquement acceptables de ce composé, pour la préparation de médicaments appropriés pour le traitement des troubles gastro-intestinaux provoqués par la sérotonine.
2. L'utilisation selon la revendication 1, caractérisée en ce que le composé utilisé est l'ester endo-8-méthyl-8-aza-bicyclo[3,2,1 ]oct-3-ylique de l'acide indole-3-yl-carboxylique.
3. L'utilisation des composés selon la revendication 1 pour la préparation d'un médicament approprié pour le traitement des troubles gastro-intestinaux choisis parmi la gastrite, l'ulcère gastro-duodénal, la dyskinésie biliaire, le côlon irritable, l'appendicite, le syndrome des intestins irritables, la maladie de Crohn, la colite ulcéreuse, le syndrome carcinoïde et les diarrhées d'origines diverses, par exemple la diarrhée secrétoire, la diarrhée provoquée par des bactéries, la diarrhée du choléra, la diarrhée du voyageur, la diarrhée psychogène ou les troubles de la motilité oesophagienne, l'achalasie, la hernie hiatale, l'insuffisance du cardia , le reflux gastro-oesophagien et gastro-duodénal, l'hypotonie stomacale, l'hypertrophie du pylore, l'iléus paralytique et la maladie de Hirschsprung.
4. L'utilisation selon la revendication 3, caractérisée en ce que le composé utilisé est l'ester endo-8-méthyl-8-aza-bicyclo[3,2,1 ]oct-3-ylique de l'acide indole-3-yl-carboxylique.
5. L'utilisation selon la revendication 3, caractérisée en ce que le trouble gastro-intestinal est le trouble du reflux gastro-oesophagien.
6. L'utilisation selon la revendication 5, caractérisée en ce que le composé utilisé est l'ester endo-8-méthyl-8-aza-bicyclo[3,2,1 ]oct-3-ylique de l'acide indole-3-yl-carboxylique.
7. L'utilisation selon la revendication 3, caractérisée en ce que le trouble gastro-intestinal est le côlon irritable.
8. L'utilisation selon la revendication 7, caractérisée en ce que le composé utilisé est l'ester endo-8-méthyl-8-aza-bicyclo[3,2,1 ]oct-3-ylique de l'acide indole-3-yl-carboxylique.
9. L'utilisation selon la revendication 7, caractérisée en ce que le trouble gastro-intestinal est le syndrome des intestins irritables.
10. L'utilisation selon la revendication 9, caractérisée en ce que le composé utilisé est l'ester endo-8-méthyl-8-aza-bicyclo[3,2,1 ]oct-3-ylique de l'acide indole-3-yl-carboxylique.
11. L'utilisation selon la revendication 3, caractérisé en ce que le trouble gastro-intestinal est la diarrhée.
12. L'utilisation selon la revendication 11, caractérisée en ce que le composé utilisé est l'ester endo-8-méthyl-8-aza-bicyclo[3,2,1 ]oct-3-ylique de l'acide indole-3-yl-carboxylique.
13. L'utilisation selon la revendication 11, caractérisée en ce que le trouble gastro-intestinal est la diarrhée secrétoire.
14. L'utilisation selon la revendication 13, caractérisée en ce que le composé utilisé est l'ester endo-8-méthyl-8-aza-bicyclo[3,2,1 ]oct-3-ylique de l'acide indole-3-yl-carboxylique.
15. L'utilisation selon la revendication 11, caractérisée en ce que le trouble gastro-intestinal est la diarrhée du voyageur.
16. L'utilisation selon la revendication 15, caractérisée en ce que le composé utilisé est l'ester endo-8-méthyl-8-aza-bicyclo[3,2,1]oct-3-ylique de l'acide indole-3-yl-carboxylique.
17. L'utilisation selon la revendication 11, caractérisée en ce que le trouble gastro-intestinal est la diarrhée provoquée par des bactéries.
18. L'utilisation selon la revendication 17, caractérisée en ce que le composé utilisé est l'ester endo-8-méthyl-8-aza-bicyclo[3,2,1]oct-3-ylique de l'acide indole-3-yl-carboxylique.
HK50996A 1984-12-20 1996-03-21 Treatment of gastrointestinal disorders using 5-ht3 antagonists HK50996A (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
DE19843446484 DE3446484A1 (de) 1984-12-20 1984-12-20 Therapeutische verwendung von benzoesaeurepiperidylestern oder -amiden
CH141485 1985-04-02
CH266785 1985-06-24
CH313085 1985-07-19
CH312985 1985-07-19
CH338385 1985-08-07
CH338285 1985-08-07
DE19853531282 DE3531282A1 (de) 1985-09-02 1985-09-02 Therap. verwendung von mono- oder dicarbocyclischen oder heterocyclischen carbonsaeure- oder sulfonsaeure-estern oder -amiden
DE19853531281 DE3531281A1 (de) 1985-09-02 1985-09-02 Therap. verwendung von mono- oder dicarbocyclischen oder heterocyclischen carbonsaeure- oder sulfonsaeure-estern oder -amiden

Publications (1)

Publication Number Publication Date
HK50996A true HK50996A (en) 1996-03-29

Family

ID=27575765

Family Applications (1)

Application Number Title Priority Date Filing Date
HK50996A HK50996A (en) 1984-12-20 1996-03-21 Treatment of gastrointestinal disorders using 5-ht3 antagonists

Country Status (10)

Country Link
EP (1) EP0189002B1 (fr)
JP (2) JPS61152628A (fr)
AT (1) ATE86110T1 (fr)
AU (1) AU595172B2 (fr)
CY (1) CY1908A (fr)
DE (1) DE3587151T2 (fr)
DK (1) DK174146B1 (fr)
HK (1) HK50996A (fr)
LU (1) LU88345I2 (fr)
PH (1) PH24193A (fr)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE201165T1 (de) * 1985-03-14 1989-04-20 Beecham Group P.L.C., Brentford Arzneimittel zur behandlung von emesis, anxietas und "irritable bowel syndrome".
GB8607662D0 (en) * 1986-03-27 1986-04-30 Rainsford K D Pharmaceutical formulation
JP2681085B2 (ja) * 1986-06-26 1997-11-19 杏林製薬株式会社 胃炎治療剤
EP0254584B1 (fr) * 1986-07-25 1992-10-07 Beecham Group Plc Composés azabicycliques, procédé pour leur préparation et leur utilisation pharmaceutique
ZA878096B (en) * 1986-11-03 1988-04-26 Merrell Dow Pharmaceuticals Inc. Esters of hexahydro-8-hydroxy-2,6-methano-2h-quinolizin-3(4h)-one and related compounds
US5198447A (en) * 1986-11-21 1993-03-30 Glaxo Group Limited Medicaments
US4948803A (en) * 1986-11-21 1990-08-14 Glaxo Group Limited Medicaments for treatment on prevention of withdrawal syndrome
EP0279990B1 (fr) * 1986-12-17 1995-07-12 Glaxo Group Limited Emploi de dérivés hétérocycliques pour le traitement de troubles de la démence
US4973594A (en) * 1986-12-17 1990-11-27 Glaxo Group Limited Medicaments
US5330982A (en) * 1986-12-17 1994-07-19 Glaxo Group Limited Pharmaceutical composition containing a 5-HT receptor antagonist and an H+ K+ Atpase inhibitor and a method of treating gastrointestingal disorders therewith
US5244909A (en) * 1986-12-17 1993-09-14 Glaxo Group Limited Methods for the treatment of cognitive disorders
GB8701022D0 (en) * 1987-01-19 1987-02-18 Beecham Group Plc Treatment
DE3852145T2 (de) * 1987-02-18 1995-04-06 Beecham Group Plc Indolderivate, Verfahren zu deren Herstellung und pharmazeutische Präparate, die diese enthalten.
FR2616149B1 (fr) * 1987-06-04 1990-10-19 Adir Nouveau derive de l'acide benzo (b) thiophene - 7 carboxylique, son procede de preparation et les compositions pharmaceutiques qui le contiennent
US5364863A (en) * 1987-09-08 1994-11-15 Eli Lilly And Company Specific 5-HT3 antagonists
NZ227229A (en) * 1987-12-10 1991-03-26 Duphar Int Res Indole derivatives and pharmaceutical compositions
DE3907388A1 (de) * 1989-03-08 1990-09-13 Kali Chemie Pharma Gmbh Verfahren zur herstellung von indolcarbonsaeurederivaten
GB8916682D0 (en) * 1989-07-21 1989-09-06 Beecham Group Plc Pharmaceutical compounds
US5140023A (en) * 1990-04-27 1992-08-18 G. D. Searle & Co. Azatetracycle compounds
GB9009542D0 (en) * 1990-04-27 1990-06-20 Beecham Group Plc Novel compounds
US5223613A (en) * 1990-04-27 1993-06-29 G. D. Searle & Co. Azatetracycle compounds and process of preparing same
HU211081B (en) * 1990-12-18 1995-10-30 Sandoz Ag Process for producing indole derivatives as serotonin antagonists and pharmaceutical compositions containing the same
CA2097815C (fr) * 1990-12-28 2001-04-17 Fumio Suzuki Derive de la quinoline
US5516782A (en) * 1991-03-07 1996-05-14 G. D. Searle & Co. New meso-azacyclic aromatic acid amides and esters as novel serotonergic agents
US5137893A (en) * 1991-03-07 1992-08-11 G. D. Searle & Co. Pharmaceutically useful meso-azacyclic amides of imidazopyridine carboxylic acids and analogs thereof
US5227377A (en) * 1991-03-07 1993-07-13 G. D. Searle & Co. Meso-azacyclic amides of certain bicyclic carboxylic acids
US5196547A (en) * 1991-03-07 1993-03-23 G. D. Searle & Co. Meso-azacyclic amides of imidazopyridine carboxylic acids and analogs thereof
US5260303A (en) * 1991-03-07 1993-11-09 G. D. Searle & Co. Imidazopyridines as serotonergic 5-HT3 antagonists
US5234921A (en) * 1991-03-07 1993-08-10 G. D. Searle & Co. Meso-azacyclic amides of imidazopyridine carboxylic acids and analogs thereof as pharmaceuticals
CA2082415A1 (fr) * 1991-03-07 1992-09-08 Daniel P. Becker Amides et esters acides aromatiques mesoazacycliques utilises comme nouveaux agents serotoninergiques
US5219850A (en) * 1991-03-07 1993-06-15 G. D. Searle & Co. Pharmaceutically useful meso-azacyclic amides of imidazopyridine carboxylic acids and analogs thereof
US5492919A (en) * 1991-08-03 1996-02-20 Smithkline Beecham P.L.C. 5-HT4 receptor antagonists
CA2116024A1 (fr) * 1991-08-20 1993-03-04 Francis David King Antagonistes des recepteurs 5-ht4
GB9214184D0 (en) * 1992-07-03 1992-08-12 Smithkline Beecham Plc Pharmaceuticals
US5840903A (en) * 1992-07-27 1998-11-24 G. D. Searle & Co. 4-aminomethyl-1-azaadamantane derived benzamides
GR1001378B (el) * 1992-10-08 1993-10-29 Smithkline Beecham Plc Ανταγωνιστές 5-ΗΤ4 πιπεριδυλαλκυλίου.
ES2056728B1 (es) * 1992-10-28 1995-05-01 Smithkline Beecham Plc Nuevos derivados de piperidilo y aminoalquilo con actividad antagonista del receptor 5-ht4
US5354757A (en) * 1992-12-15 1994-10-11 G. D. Searle & Co. Azanoradamantanes
JP3235913B2 (ja) * 1993-07-30 2001-12-04 エーザイ株式会社 アミノ安息香酸誘導体
US5530018A (en) * 1994-02-04 1996-06-25 G. D. Searle & Co. Meso-azanoradamantanes
US5399562A (en) * 1994-02-04 1995-03-21 G. D. Searle & Co. Indolones useful as serotonergic agents
GB9406857D0 (en) * 1994-04-07 1994-06-01 Sandoz Ltd Improvements in or relating to organic compounds
ES2327600T3 (es) 1999-02-18 2009-11-02 Novasearch Ag Uso de antagonistas del receptor de la 5-ht3 para el tratamiento de enfermedades musculoesqueleticas.
WO2000048597A1 (fr) 1999-02-18 2000-08-24 Novartis Ag Utilisation systemique d'antagonistes du recepteur 5-ht3 contre des processus inflammatoires rhumatismaux
WO2001064202A2 (fr) 2000-03-01 2001-09-07 Euro-Celtique S.A. Traitement de troubles gastro-intestinaux fonctionnels
AU2003252738A1 (en) * 2002-08-09 2004-02-25 Ajinomoto Co., Inc. Remedy for intestinal diseases and visceral pain
KR100812499B1 (ko) * 2006-10-16 2008-03-11 이도훈 항경련제
KR20110071014A (ko) 2008-10-17 2011-06-27 위스콘신 얼럼나이 리서어치 화운데이션 생물학적으로 활성인 알파-베타 펩티드의 제조 방법

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL59004A0 (en) * 1978-12-30 1980-03-31 Beecham Group Ltd Substituted benzamides their preparation and pharmaceutical compositions containing them
FR2493848B2 (fr) * 1980-11-07 1986-05-16 Delalande Sa Nouveaux derives des nor-tropane et granatane, leur procede de preparation et leur application en therapeutique
EP0069481A1 (fr) * 1981-06-17 1983-01-12 Beecham Group Plc Azabicycloalkylbenzamides, leur procédé de préparation et les compositions pharmaceutiques les contenant
EP0068700A1 (fr) * 1981-06-29 1983-01-05 Beecham Group Plc Azabicycloalkylbenzamides, leur procédé de préparation et les compositions pharmaceutiques les contenant
EP0069482A1 (fr) * 1981-06-29 1983-01-12 Beecham Group Plc Azabicycloalkylenzamides, leur procédé de préparation et les compositions pharmaceutiques les contenant
AU1508183A (en) * 1982-06-04 1983-12-08 Beecham Group Plc Benzamide and anilide derivatives of 8-azabicyclo-(3.2.1)- -octane
FI74707C (fi) * 1982-06-29 1988-03-10 Sandoz Ag Foerfarande foer framstaellning av terapeutiskt anvaendbara alkylenoeverbryggade piperidylestrar eller -amider av bicykliska karboxylsyror.
BE897117A (fr) * 1982-06-29 1983-12-23 Sandoz Sa Nouveaux derives de la piperidine leur preparation et leur utilisation comme medicaments
EP0101641A3 (fr) * 1982-07-22 1984-03-28 Beecham Group Plc Dérivés sulphonylamino-aza-bicycloalkyles
EP0102195A3 (fr) * 1982-08-03 1984-04-11 Beecham Group Plc Dérivés d'azabicycloalkyle substitués doués d'une activité dopamine antagoniste
EP0135545A1 (fr) * 1983-02-19 1985-04-03 Beecham Group Plc Derives anylides et benzamides d'azabicycloalkyle
DE3429830A1 (de) * 1983-08-26 1985-03-07 Sandoz-Patent-GmbH, 7850 Lörrach Automatische carbonsaeure- und sulfonsaeureester oder -amide
DE201165T1 (de) * 1985-03-14 1989-04-20 Beecham Group P.L.C., Brentford Arzneimittel zur behandlung von emesis, anxietas und "irritable bowel syndrome".

Also Published As

Publication number Publication date
AU595172B2 (en) 1990-03-29
ATE86110T1 (de) 1993-03-15
JPH0588207B2 (fr) 1993-12-21
DK591385A (da) 1986-06-21
DE3587151D1 (de) 1993-04-08
EP0189002A3 (en) 1990-01-31
EP0189002B1 (fr) 1993-03-03
JPS61152628A (ja) 1986-07-11
DK174146B1 (da) 2002-07-22
AU5139685A (en) 1986-07-31
DK591385D0 (da) 1985-12-18
PH24193A (en) 1990-04-10
CY1908A (en) 1985-12-13
DE3587151T2 (de) 1993-07-15
LU88345I2 (fr) 1994-05-04
EP0189002A2 (fr) 1986-07-30
JPH02237920A (ja) 1990-09-20

Similar Documents

Publication Publication Date Title
EP0189002B1 (fr) Traitement de maladies gastro-intestinales utilisant des 5-HT3 antagonistes
US4910193A (en) Treatment of gastrointestinal disorders
US4826838A (en) Analgesic carbocyclic and heterocyclic carbonylmethylene-and carbonylmethypipidines and-pyrrolidines
AU620421B2 (en) Treatment of gastrointestinal disorders
US4605652A (en) Method of enhancing memory or correcting memory deficiency with arylamido (and arylthioamido)-azabicycloalkanes
FI98367C (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten trisyklisten, typpipitoisten yhdisteiden valmistamiseksi
US5011846A (en) Medicament compositions derived from quinolizine and quinolizinone and methods of use thereof
CA1333154C (fr) Composes r-n-(1-azabicyclo(2.2.2)oct-3-yl) benzamides et thiobenzamides ameliorant la memoire
CZ290115B6 (cs) Farmaceutický prostředek
HUT60270A (en) Process for producing alpha-oxoacetamide derivatives and pharmaceutical compositions comprising such derivatives as active ingredient
JPH08509238A (ja) Ｇａｂａアゴニストの新規医学的用途
PT99518A (pt) Processo para a preparacao de novos compostos triciclicos por exemplo derivados de piridoindole
US4935511A (en) Benzoxazine and benzoxazepine carboxamide 5-HT3 antagonists
JPH05132430A (ja) 薬物従属症及び禁断症状の治療に関するグリシン／ｎｍｄａレセプターリガンドの用法
US6967207B2 (en) Preventive or therapeutic agents for gastric or esophageal regurgitation
EP0467365A2 (fr) Utilisation d&#39;un antagoniste des récepteurs de type 3 de la 5-hydroxytryptamine pour la préparation d&#39;une composition pharmaceutique pour traiter l&#39;incontinence urinaire
Burke et al. Regionally selective cholinergic stimulation by BRL 24924 in the human isolated gut.
MXPA06002139A (es) Composiciones utiles para tratar trastornos de la motilidad gastrointestinal.
Colpaert et al. Discriminative stimulus properties of xylazine in rat: discriminability and effects of putative alpha-2 adrenoceptor agonists and antagonists.
Costall et al. The action of dazopride to enhance gastric emptying and block emesis
EP0329932B1 (fr) Utilisation des dérivés de la quinolizine et de la quinolizinone pour la manufacture des médicaments
JP2002517448A (ja) 精神障害の治療用ｎｋ−１受容体アンタゴニストの使用
JPH08143573A (ja) 腸管運動機能不全性疾患の治療剤
PT87781B (pt) Processo para a preparacao de 8 alfa-acilaminoergolina e de composicoes farmaceuticas que a contem
Engel et al. 5-HT3 receptors in the gastrointestinal tract

Legal Events

Date Code Title Description
PF Patent in force
PE Patent expired

Effective date: 20051212